A clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. We are pioneering a precision gene editing approach to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome.
Lead Underwriter
BofA Securities, Inc, Cowen and Company, LLC , Morgan Stanley & Co. LLC, SVB Leerink LLC
